Figure 1c Figure 1d Figure 1g Figure 1f Supplementary Figure 1c - PowerPoint PPT Presentation

Figure 1c Figure 1d

Figure 1g

Figure 1f

Supplementary Figure 1c

Supplementary Figure 1g

Figure 5e, right panels. WT+Rap WT+Rap WT Con WT Con DDX6 ESC #2 DDX6 ESC #2 WT+HBSS WT+HBSS WT+RAP WT+RAP Actin LC3 WT Con WT Con DDX6 ESC #2 DDX6 ESC #2 WT+HBSS WT+HBSS WT+RAP WT+RAP Actin SQSTM1

Figure 6h, right panels. Con Con Con+Rap Con+Rap DDX6 oe DDX6 oe GFP ‐ DDX6 Nat ‐ DDX6 Con Con+Rap Con Con+Rap DDX6 oe DDX6 oe Actin SQSTM1

Control Patient For Figure 7f Control Patient 260 260 140 140 100 100 70 70 50 50 37 37 Dcp2 ‐ ab WB pDcp2 ‐ ab WB Control Patient Control Patient 260 260 140 140 100 100 70 70 50 50 37 37 Actin WB SQSTM1 WB

Fig.4C:3XFLAG Dcp2 IP Supp Fig. 7: In vitro mTor assay Supp Fig. 7: In vitro mTor assay 260 140 100 70 50 Supp.Fig.2b VAD1 Overexpression Supp Fig.7:+CiAP ‐ Dcp2 Ab Supp Fig.7:+CiAP ‐ phospho ‐ Dcp2 Ab